{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:48:20Z","timestamp":1768434500713,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T00:00:00Z","timestamp":1502755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T00:00:00Z","timestamp":1502755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Isolated pelvic perfusion (IPP) can be used to treat unresectable melanoma metastases of the pelvis. IPP can be performed either by surgical or percutaneous approaches, using different balloon catheters. The aim of this study was to examine whether the surgical and percutaneous approaches were comparable with respect to tumor drug exposure in the pelvis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A pharmacokinetic study was performed in 5 melanoma patients treated with surgical IPP and five with percutaneous IPP. Both groups received melphalan at the dose of 30\u00a0mg\/m<jats:sup>2<\/jats:sup>. Melphalan pharmacokinetic analyses were performed and the main parameter used to evaluate pelvic tumor drug-exposure was the ratio of areas under the melphalan plasma concentration curves in the pelvis and the systemic compartment, during the perfusion time (AUC<jats:sub>0 to 20<\/jats:sub>). Non-parametric Mann\u2013Whitney tests were employed for statistical comparisons.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median and interquartile range (IQR) values of the ratios between melphalan AUC<jats:sub>0 to 20<\/jats:sub> in pelvic and systemic compartments were 7.9 (IQR 7.2 to 9.9) and 5 (IQR 4 to 7.9) for surgical and percutaneous IPPs, respectively (p\u00a0=\u00a00.209).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Tumor exposure to drug using these two methods did not statistically differ and both methods, therefore, can be adopted interchangeably, utilizing a perfusion blood flow rate of approximately 120\u00a0ml\/min. The small sample size is a limitation of this study but our preliminary results can be used to calculate the effect size of a larger trial.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration<\/jats:italic> Clinical Trials.gov Identifier NCT01920516; date of trial registration: August 6, 2013<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-017-2738-y","type":"journal-article","created":{"date-parts":[[2017,8,15]],"date-time":"2017-08-15T10:55:09Z","timestamp":1502794509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability"],"prefix":"10.1186","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct01920516","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-084X","authenticated-orcid":false,"given":"Stefano","family":"Guadagni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giammaria","family":"Fiorentini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Marsili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo Victor","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Masedu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,8,15]]},"reference":[{"key":"2738_CR1","first-page":"1005","volume":"70","author":"CT Klopp","year":"1953","unstructured":"Klopp CT. Regional intra-arterial nitrogen mustard as an adjunct to radiation therapy. Am J Roentgenol Radium Ther Nucl Med. 1953;70:1005\u201314.","journal-title":"Am J Roentgenol Radium Ther Nucl Med."},{"key":"2738_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","volume":"148","author":"O Creech","year":"1958","unstructured":"Creech O, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148:616\u201332.","journal-title":"Ann Surg"},{"key":"2738_CR3","first-page":"464","volume":"111","author":"E Watkins Jr","year":"1960","unstructured":"Watkins E Jr, Hering AC, Luna R, et al. The use of intravascular balloon catheters for isolation of the pelvic vascular bed during pump-oxygenator perfusion of cancer chemotherapy agents. Surg Gynecol Obstet. 1960;111:464\u20138.","journal-title":"Surg Gynecol Obstet."},{"key":"2738_CR4","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.soc.2008.04.014","volume":"17","author":"G Begossi","year":"2008","unstructured":"Begossi G, Belliveau JF, Wanebo HJ. Pelvic perfusion for advanced colorectal cancers. Surg Oncol Clin N Am. 2008;17:825\u201342.","journal-title":"Surg Oncol Clin N Am"},{"key":"2738_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1002\/j.1552-4604.1998.tb04390.x","volume":"38","author":"S Guadagni","year":"1998","unstructured":"Guadagni S, Aigner KR, Palumbo G, et al. Pharmacokinetics of mitomycin C in pelvic stopflow infusion and hypoxic pelvic perfusion with and without hemofiltration: a pilot study of patients with recurrent unresectable rectal cancer. J Clin Pharmacol. 1998;38:936\u201344.","journal-title":"J Clin Pharmacol"},{"key":"2738_CR6","first-page":"6","volume":"7","author":"KR Aigner","year":"1994","unstructured":"Aigner KR, Kaevel K. Pelvic stopflow infusion (PSI) and hypoxic pelvic perfusion (HPP) with mitomycin and melphalan for recurrent rectal cancer. Reg Cancer Treat. 1994;7:6\u201311.","journal-title":"Reg Cancer Treat."},{"key":"2738_CR7","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/archsurg.1993.01420170067009","volume":"128","author":"PS Turk","year":"1993","unstructured":"Turk PS, Belliveau JF, Darnowski JW, et al. Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique. Arch Surg. 1993;128:533\u20139.","journal-title":"Arch Surg"},{"key":"2738_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ejso.2004.03.015","volume":"30","author":"MG van Ijken","year":"2004","unstructured":"van Ijken MG, van Etten B, Guetens G, et al. Balloon catheter hypoxic abdominal and pelvic perfusion with tumor necrosis factor-alpha, melphalan and mitomycin C: a pharmacokinetic study in pigs. Eur J Surg Oncol. 2004;30:699\u2013707.","journal-title":"Eur J Surg Oncol"},{"key":"2738_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.ejso.2005.06.004","volume":"31","author":"MG van Ijken","year":"2005","unstructured":"van Ijken MG, van Etten B, Guetens G, et al. Balloon catheter hypoxic pelvic perfusion with mitomycin C and melphalan for locally advanced tumours in the pelvic region: a phase I\u2013II trial. Eur J Surg Oncol. 2005;31:897\u2013904.","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl 1","key":"2738_CR10","first-page":"51","volume":"6","author":"JF Thompson","year":"1993","unstructured":"Thompson JF, Waugh RC, Kam P. Stop-flow cytotoxic infusion. A simplified technique using percutaneous catheters. Reg Cancer Treat. 1993;6(Suppl 1):51.","journal-title":"Reg Cancer Treat"},{"key":"2738_CR11","first-page":"202","volume":"7","author":"JF Thompson","year":"1994","unstructured":"Thompson JF, Liu M, Waugh RC, et al. A percutaneous aortic \u201cstop-flow\u201d infusion technique for regional cytotoxic therapy of the abdomen and pelvis. Reg Cancer Treat. 1994;7:202\u20137.","journal-title":"Reg Cancer Treat."},{"key":"2738_CR12","first-page":"246","volume":"93","author":"S Ricci","year":"1997","unstructured":"Ricci S, Rossi G, Roversi R, et al. Antiblastic locoregional perfusion with control of the aorto-caval flow: technique of percutaneous access. Radiol Med. 1997;93:246\u201352.","journal-title":"Radiol Med."},{"key":"2738_CR13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/SLA.0b013e318242ebe7","volume":"255","author":"S Bonvalot","year":"2012","unstructured":"Bonvalot S, de Baere T, Mendiboure J, et al. Hyperthermic pelvic perfusion with tumor necrosis factor-\u03b1 for locally advanced cancers. Encouraging results of a phase II study. Ann Surg. 2012;255:281\u20136.","journal-title":"Ann Surg"},{"key":"2738_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1177\/0284185113507253","volume":"55","author":"S Murata","year":"2014","unstructured":"Murata S, Onozawa S, Kim C, et al. Negative-balance isolated pelvic perfusion inpatients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. Acta Radiol. 2014;55:793\u2013801.","journal-title":"Acta Radiol"},{"key":"2738_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0002-9610(01)00841-8","volume":"183","author":"S Guadagni","year":"2002","unstructured":"Guadagni S, Russo F, Rossi CR, et al. Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Surg. 2002;183:28\u201336.","journal-title":"Am J Surg"},{"key":"2738_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00008390-200302000-00009","volume":"13","author":"S Guadagni","year":"2003","unstructured":"Guadagni S, Santinami M, Patuzzo R, et al. Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma: a pilot study. Melanoma Res. 2003;13:51\u20138.","journal-title":"Melanoma Res"},{"key":"2738_CR17","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Song SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol"},{"key":"2738_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","volume":"2","author":"CC Schag","year":"1984","unstructured":"Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187\u201393.","journal-title":"J Clin Oncol"},{"key":"2738_CR19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s002800050611","volume":"39","author":"FB Pruijn","year":"1997","unstructured":"Pruijn FB, van Daalen M, Holford NH, et al. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol. 1997;39:541\u20136.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2738_CR20","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.soc.2008.04.003","volume":"17","author":"PCA Kam","year":"2008","unstructured":"Kam PCA, Thompson JF. Pharmacokinetics of regional therapy: isolated limb infusion and other low flow techniques for extremity melanoma. Surg Oncol Clin N Am. 2008;17:795\u2013804.","journal-title":"Surg Oncol Clin N Am"},{"key":"2738_CR21","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1016\/j.jchromb.2009.07.033","volume":"877","author":"A Mirkou","year":"2009","unstructured":"Mirkou A, Vignal B, Cohen S, et al. Assay for the quantification of melphalan and its hydrolysis products in human plasma by liquid chromatography\u2013tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2009;877:3089\u201396.","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci."},{"issue":"3","key":"2738_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","volume":"99","author":"Y Zhang","year":"2010","unstructured":"Zhang Y, Huo M, Zhou J, Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Progr Biomed. 2010;99(3):306\u201314.","journal-title":"Comput Methods Progr Biomed"},{"key":"2738_CR23","unstructured":"World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. WHO offset publication No. 48."},{"key":"2738_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.bjc.6690335","volume":"80","author":"JH de Wilt","year":"1999","unstructured":"de Wilt JH, Manusama ER, van Tiel ST, et al. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats. Br J Cancer. 1999;80:161\u20136.","journal-title":"Br J Cancer"},{"key":"2738_CR25","first-page":"61","volume-title":"Induction chemotherapy. Systemic and locoregional","author":"G Fiorentini","year":"2016","unstructured":"Fiorentini G, Cantore M, Montagnani F, et al. The role of hypoxia and hyperthermia in chemotherapy. In: Aigner KR, Stephens FO, editors. Induction chemotherapy. Systemic and locoregional. Berlin: Springer-Verlag; 2016. p. 61\u201371."},{"key":"2738_CR26","first-page":"248","volume":"50","author":"W Lawrence Jr","year":"1961","unstructured":"Lawrence W Jr, Kuehn P, Mori S, et al. Regional perfusion of the pelvis: consideration of the \u201cleakage\u201d problem. Surgery. 1961;50:248\u201359.","journal-title":"Surgery"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-017-2738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-017-2738-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-017-2738-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:46:38Z","timestamp":1628613998000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-017-2738-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,15]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2738"],"URL":"https:\/\/doi.org\/10.1186\/s13104-017-2738-y","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,15]]},"assertion":[{"value":"13 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"411"}}